Stocks · News reference
LeonaBio, Inc. (NASDAQ:LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that its lead product candidate,
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
On August 26, 2026, LeonaBio, Inc. (the "Company") announced that it had enrolled the 500th subject in its ongoing Phase 3 ELAINE-3 clinical trial (NCT05696626) for lasofoxifene in combination with abemaciclib,
Mizuho analyst Graig Suvannavejh maintains LeonaBio (NASDAQ:LONA) with a Outperform and lowers the price target from $16 to $15.
Citizens analyst Jason N. Butler maintains LeonaBio (NASDAQ:LONA) with a Market Outperform and lowers the price target from $18 to $17.
LeonaBio (NASDAQ:LONA) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(1.36) by 41.18 percent. This is a 55.56 percent increase over losses of $(1.80) per share from the